Skip to contentB
Bio-Rad Laboratories, Inc.
B
BIOBio-Rad Laboratories, Inc. Q1 2024 · 10-Q
Revenue$610.80M$610.80M−9.8% vs Q1 2023 Net Income$383.90M$383.90M+456.4% vs Q1 2023 EPS Diluted$13.45$13.45+479.7% vs Q1 2023 Gross Profit$325,900,000−10.1% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Bio-Rad Laboratories, Inc. · CIK 12208 · Engraved from SEC EDGAR
Operating Cash Flow$69,800,000−28.9% Free Cash Flowderived$29,600,000−52.6% Margins · derivedGross margin53.4%−0.2 pt vs Q1 2023
Operating margin7.3%−1.8 pt vs Q1 2023
Net margin62.9%+52.7 pt vs Q1 2023
ended Mar 31, 2024 · filed May 8, 2024 · 38 d after period end